Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose of sorafenib
up to the full active dose when combined with standard weekly dosing of topotecan in patients
with recurrent small cell lung cancer and to characterize the toxicities associated with the
combination of topotecan and sorafenib in this patient population